Cyted Health

Cyted Health is a biotechnology company based in Cambridge, United Kingdom, that specializes in gastrointestinal molecular diagnostics. Founded in 2020 as a spinout from the University of Cambridge, the company focuses on developing non-endoscopic diagnostic platforms aimed at early detection and monitoring of esophageal conditions, including pre-cancerous and cancerous diseases. Cyted Health's flagship product, EndoSign®, is an FDA-cleared device that allows for minimally invasive cell collection from the esophagus. This innovative approach enhances patient access and comfort compared to traditional endoscopy. The company is actively involved in clinical studies to improve screening and monitoring for conditions like Barrett's Esophagus and Eosinophilic Esophagitis. With over 35,000 tests completed in the UK's National Health Service, Cyted Health is committed to advancing digestive health through its proprietary biomarker discovery and AI-driven diagnostic tools.